SPOTLIGHT: Big Pharma takes an interest in cancer vaccines

For two decades, companies have struggled to develop therapeutic vaccines designed to treat cancer by stimulating the immune system to attack cancer cells without harming normal cells. So far, the FDA has yet to approve a single therapeutic cancer vaccine. But a crop of late-stage cancer vaccines are showing a lot of promise and attracting the attention of pharma and biotech companies. Check out this report for a look at some of the late-stage drug candidates that could revolutionize the cancer treatment field. Article